Fuzionaire to Collaborate with McGill University to Advance Chemistry Platform for Incorporation of Silicon into Pharmaceuticals
New silicon-based drugs made with Fuzionaire’s proprietary alkali metal catalyst platform could offer improved efficacy and reduced toxicity THE WOODLANDS, Texas–(BUSINESS WIRE)–Fuzionaire, Inc. today announced a collaborative research agreement with McGill University that will leverage the company’s proprietary alkali metal catalyst platform in creating novel heterocyclic, biologically active, silicon-containing scaffolds and new silicon-based drug candidates. … [Read more…]
